After this evening's 9.5% surge to $80.99 per share, Blueprint Medicines might just keep moving past its target price of $79.5. With an average analyst rating of buy, and target prices from $50.0 to $114.0, the stock's next move is anyone's guess.
Blueprint Medicines has an average level of shares sold short, at 9.2% of its total share float. The stock's short ratio (also called days to cover) is 4.51. Only 0.79% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders.
Institutional investors own 108.3% of Blueprint Medicines's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Blueprint Medicines
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | Blackrock Inc. | 11% | 6,587,784 | $533,544,612 |
| 2023-09-30 | FMR, LLC | 10% | 6,085,255 | $492,844,789 |
| 2023-09-30 | Vanguard Group Inc | 10% | 5,967,143 | $483,278,898 |
| 2023-09-30 | Price (T.Rowe) Associates Inc | 9% | 5,496,577 | $445,167,759 |
| 2023-09-30 | Wellington Management Group, LLP | 8% | 5,080,521 | $411,471,384 |
| 2023-09-30 | Rock Springs Capital Management, LP | 4% | 2,685,294 | $217,481,955 |
| 2023-09-30 | State Street Corporation | 4% | 2,625,627 | $212,649,525 |
| 2023-09-30 | T. Rowe Price Investment Management, Inc. | 4% | 2,458,169 | $199,087,102 |
| 2023-09-30 | JP Morgan Chase & Company | 3% | 1,694,217 | $137,214,631 |
| 2023-09-30 | Macquarie Group Limited | 3% | 1,579,842 | $127,951,400 |
